Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zai Lab LtdZLAB · Entity 4271 | Director · Chairperson & CEO | July 01, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zai Lab Ltd
Report date July 01, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 1,221,401 |
Last balance in matching sequence
After 2026-07-02 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2026-07-01 · Exercise / conversion · Acquired 18,000 · Balance 1,221,784 F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2: ADSs acquired upon vesting of Restricted Share Units ("RSUs"). F3: Each RSU represents a contingent right to receive one ADS. Row 2 · 2026-07-01 · Tax withholding · Disposed 7,083 · Balance 1,214,701 F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F4: These ADSs were withheld to cover taxes upon vesting of RSUs. Row 3 · 2026-07-02 · Exercise / conversion · Acquired 11,048 · Balance 1,225,749 F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2: ADSs acquired upon vesting of Restricted Share Units ("RSUs"). F3: Each RSU represents a contingent right to receive one ADS. Row 4 · 2026-07-02 · Tax withholding · Disposed 4,348 · Balance 1,221,401 F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F4: These ADSs were withheld to cover taxes upon vesting of RSUs. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 36,000 |
Reported balance
After 2026-07-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-01 · Exercise / conversion · Disposed 18,000 · Balance 36,000 F3: Each RSU represents a contingent right to receive one ADS. F5: The RSUs vest in equal annual installments over four years beginning on 07/01/2025, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered in the form of ADSs to the reporting person following vesting. F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 33,146 |
Reported balance
After 2026-07-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-02 · Exercise / conversion · Disposed 11,048 · Balance 33,146 F3: Each RSU represents a contingent right to receive one ADS. F6: The RSUs vest in equal annual installments over four years beginning on 07/02/2026, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered in the form of ADSs to the reporting person following vesting. F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 80,393 |
Reported balance
After 2026-07-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-02 · Grant · Acquired 80,393 · Balance 80,393 F3: Each RSU represents a contingent right to receive one ADS. F7: The RSUs vest in equal annual installments over four years beginning on 07/02/2027, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered in the form of ADSs to the reporting person following vesting. F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F2: ADSs acquired upon vesting of Restricted Share Units ("RSUs").
F3: Each RSU represents a contingent right to receive one ADS.
F4: These ADSs were withheld to cover taxes upon vesting of RSUs.
F5: The RSUs vest in equal annual installments over four years beginning on 07/01/2025, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.
F6: The RSUs vest in equal annual installments over four years beginning on 07/02/2026, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.
F7: The RSUs vest in equal annual installments over four years beginning on 07/02/2027, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 06, 2021 Filed Apr 7, 2021 23:55 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 1,484 | $129.21 | $191,747.64 |
DisclosureSEC source: 0000899243-21-015354 · doc4.xml · nonDerivative · entry 16 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 919,477 F1 · kind: This transaction was automatically triggered pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F17 · price: Reflects a weighted average sale price of $129.21 per share, at prices ranging from $129.02 to $129.44 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 06, 2021 Filed Apr 7, 2021 23:55 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 9,689 | $128.38 | $1,243,873.82 |
DisclosureSEC source: 0000899243-21-015354 · doc4.xml · nonDerivative · entry 15 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920,961 F1 · kind: This transaction was automatically triggered pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F16 · price: Reflects a weighted average sale price of $128.38 per share, at prices ranging from $127.95 to $128.91 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 06, 2021 Filed Apr 7, 2021 23:55 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 19,444 | $127.55 | $2,480,082.20 |
DisclosureSEC source: 0000899243-21-015354 · doc4.xml · nonDerivative · entry 14 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 930,650 F1 · kind: This transaction was automatically triggered pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F15 · price: Reflects a weighted average sale price of $127.55 per share, at prices ranging from $126.94 to $127.94 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 06, 2021 Filed Apr 7, 2021 23:55 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 2,023 | $126.62 | $256,152.26 |
DisclosureSEC source: 0000899243-21-015354 · doc4.xml · nonDerivative · entry 13 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 950,094 F1 · kind: This transaction was automatically triggered pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F14 · price: Reflects a weighted average sale price of $126.62 per share, at prices ranging from $125.93 to $126.92 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 06, 2021 Filed Apr 7, 2021 23:55 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 860 | $125.25 | $107,715.00 |
DisclosureSEC source: 0000899243-21-015354 · doc4.xml · nonDerivative · entry 12 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 952,117 F1 · kind: This transaction was automatically triggered pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F13 · price: Reflects a weighted average sale price of $125.25 per share, at prices ranging from $124.92 to $125.71 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 06, 2021 Filed Apr 7, 2021 23:55 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 3,614 | $124.39 | $449,545.46 |
DisclosureSEC source: 0000899243-21-015354 · doc4.xml · nonDerivative · entry 11 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 952,977 F1 · kind: This transaction was automatically triggered pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F12 · price: Reflects a weighted average sale price of $124.39 per share, at prices ranging from $123.89 to $124.81 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 06, 2021 Filed Apr 7, 2021 23:55 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 1,278 | $123.20 | $157,449.60 |
DisclosureSEC source: 0000899243-21-015354 · doc4.xml · nonDerivative · entry 10 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 956,591 F1 · kind: This transaction was automatically triggered pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F11 · price: Reflects a weighted average sale price of $123.20 per share, at prices ranging from $122.79 to $123.60 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 23:55 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 589 | $132.42 | $77,995.38 |
DisclosureSEC source: 0000899243-21-015354 · doc4.xml · nonDerivative · entry 9 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 957,869 F1 · kind: This transaction was automatically triggered pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F10 · price: Reflects a weighted average sale price of $132.42 per share, at prices ranging from $132.41 to $133.23 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 23:55 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 492 | $131.09 | $64,496.28 |
DisclosureSEC source: 0000899243-21-015354 · doc4.xml · nonDerivative · entry 8 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 958,458 F1 · kind: This transaction was automatically triggered pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F9 · price: Reflects a weighted average sale price of $131.09 per share, at prices ranging from $131.09 to $131.76 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 23:55 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 1,817 | $129.63 | $235,537.71 |
DisclosureSEC source: 0000899243-21-015354 · doc4.xml · nonDerivative · entry 7 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 958,950 F1 · kind: This transaction was automatically triggered pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F8 · price: Reflects a weighted average sale price of $129.63 per share, at prices ranging from $129.20 to $130.04 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 23:55 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 2,700 | $128.65 | $347,355.00 |
DisclosureSEC source: 0000899243-21-015354 · doc4.xml · nonDerivative · entry 6 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 960,767 F1 · kind: This transaction was automatically triggered pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F7 · price: Reflects a weighted average sale price of $128.65 per share, at prices ranging from $128.19 to $129.19 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 23:55 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 4,510 | $127.69 | $575,881.90 |
DisclosureSEC source: 0000899243-21-015354 · doc4.xml · nonDerivative · entry 5 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 963,467 F1 · kind: This transaction was automatically triggered pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F6 · price: Reflects a weighted average sale price of $127.69 per share, at prices ranging from $127.16.10 to $128.16 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 23:55 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 8,690 | $126.45 | $1,098,850.50 |
DisclosureSEC source: 0000899243-21-015354 · doc4.xml · nonDerivative · entry 4 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 967,977 F1 · kind: This transaction was automatically triggered pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F5 · price: Reflects a weighted average sale price of $126.45 per share, at prices ranging from $126.12 to $127.12 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 23:55 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 20,494 | $125.70 | $2,576,095.80 |
DisclosureSEC source: 0000899243-21-015354 · doc4.xml · nonDerivative · entry 3 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 976,667 F1 · kind: This transaction was automatically triggered pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · price: Reflects a weighted average sale price of $125.70 per share, at prices ranging from $125.11 to $126.11per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 23:55 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 11,492 | $124.63 | $1,432,247.96 |
DisclosureSEC source: 0000899243-21-015354 · doc4.xml · nonDerivative · entry 2 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 997,161 F1 · kind: This transaction was automatically triggered pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Reflects a weighted average sale price of $124.63 per share, at prices ranging from $124.10 to $125.10 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2021 Filed Jun 3, 2021 00:57 UTC Amendment | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionStock Options (Right to Buy) · Derivative | 111,112 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001567619-21-011576 · doc1.xml · derivative · entry 3 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,444,720 Underlying: Ordinary Shares · 111,112 shares Expires 2025-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On April 7, 2021, the Reporting Person filed a Form 4 which inadvertently did not report that she exercised 111,112 Stock Options in connection with the sales of Ordinary Shares reported in such filing. However, as reported in this amendment, the Reporting Person exercised 111,112 Stock Options for Ordinary Shares, granted to her in connection with a stock option plan that fully vested on October 22, 2020. Accordingly, Table I, Column 5 is amended to reflect such acquisition of Ordinary Shares, pursuant to such exercise of Stock Options, giving effect to the various sale transactions previously reported on the initial filing of this Form 4. F2 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1931. F3 · derivative.exercise_date: The Stock Options fully vested as of October 22, 2020. Read SEC document |
| April 05, 2021 Filed Jun 3, 2021 00:57 UTC Amendment | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionOrdinary Shares | 111,112 | $0.60 | $66,667.20 |
DisclosureSEC source: 0001567619-21-011576 · doc1.xml · nonDerivative · entry 1 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,119,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On April 7, 2021, the Reporting Person filed a Form 4 which inadvertently did not report that she exercised 111,112 Stock Options in connection with the sales of Ordinary Shares reported in such filing. However, as reported in this amendment, the Reporting Person exercised 111,112 Stock Options for Ordinary Shares, granted to her in connection with a stock option plan that fully vested on October 22, 2020. Accordingly, Table I, Column 5 is amended to reflect such acquisition of Ordinary Shares, pursuant to such exercise of Stock Options, giving effect to the various sale transactions previously reported on the initial filing of this Form 4. F2 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1931. F1 · balance_after: On April 7, 2021, the Reporting Person filed a Form 4 which inadvertently did not report that she exercised 111,112 Stock Options in connection with the sales of Ordinary Shares reported in such filing. However, as reported in this amendment, the Reporting Person exercised 111,112 Stock Options for Ordinary Shares, granted to her in connection with a stock option plan that fully vested on October 22, 2020. Accordingly, Table I, Column 5 is amended to reflect such acquisition of Ordinary Shares, pursuant to such exercise of Stock Options, giving effect to the various sale transactions previously reported on the initial filing of this Form 4. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 01:46 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantRestricted Share Units · Derivative | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-014989 · doc4.xml · derivative · entry 2 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Ordinary Shares · 17,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one Ordinary Share of the issuer. F3 · derivative.exercise_date: The Restricted Share Units vest in equal annual installments over five years beginning on 04/01/2022, the first anniversary of the date of grant. Vested shares will be delivered to the reporting person following vesting. F3 · derivative.expiration_date: The Restricted Share Units vest in equal annual installments over five years beginning on 04/01/2022, the first anniversary of the date of grant. Vested shares will be delivered to the reporting person following vesting. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 01:46 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantStock Options (Right to Buy) · Derivative | 87,000 | $0.00 Strike: $130.96 | $0.00 |
DisclosureSEC source: 0000899243-21-014989 · doc4.xml · derivative · entry 1 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,000 Underlying: Ordinary Shares · 87,000 shares Expires 2031-04-01 F1 · derivative.exercise_date: The Stock Options vest in equal annual installments over five years beginning on 04/01/2022, the first anniversary of the date of grant. Read SEC document |
| April 01, 2021 Filed Apr 7, 2021 23:55 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GiftOrdinary Shares | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-015354 · doc4.xml · nonDerivative · entry 1 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,008,653 F2 · price: On April 1, 2021, the Reporting Person made a charitable gift of 16,000 Ordinary Shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.